Anti‐interleukin (IL)‐4 and ‐IL‐5 antibodies downregulate IgE and eosinophilia in mice exposed to Aspergillus antigens

V. Kurup,P. S. Murali,J. Guo,H. Choi,B. Banerjee,J. Fink,R. Coffman
DOI: https://doi.org/10.1111/j.1398-9995.1997.tb02526.x
1997-12-01
Abstract:The effect of multiple divided doses compared with single‐dose injections of antibodies to murine interleukin (IL)‐4 and IL‐5 in their respective downregulation of IgE and eosinophilia developing in a model of allergic aspergillosis is investigated. BALB/c mice were exposed to Aspergillus fumigatus antigens (Af) before and along with anticytokine antibodies. The kinetics of blood eosinophils, eosinophil peroxidase (EPO) in bone‐marrow cells, scrum levels of IgE and Af‐specific antibodies, Af‐induced cytokine production and mRNA, and lung histology were studied. The results indicate that only multiple anti‐IL‐5 antibodies were effective in maintaining baseline levels of blood eosinophils. Multiple anti‐IL‐4 antibodies also downregulated eosinophils in the bone marrow, lung, and peripheral blood, although to a lesser extent than in anti‐IL‐5 antibody‐injected mice. Significant correlation between the EPO activity and the eosinophil numbers in anticytokine antibody‐treated mice was observed. The different anti‐IL‐4 antibody treatments downregulated IgE to the same extent. We conclude that multiple divided doses of anti‐IL‐5 antibodies arc required to sustain normal eosinophil levels in murine allergic aspergillosis. This information may be significant in the therapy of pulmonary allergic diseases.
What problem does this paper attempt to address?